通过生物异构体替代和多阶段虚拟查,以驱动方式识别强大的CDK9抑制剂
Juliana Amorim1, Luis Altamirano2, Denise Silva de Souza3
1Academic Unit of Health and Wellness, Universidad Católica de Cuenca, Cuenca, 010105, Ecuador. julianacarolinaamorim@gmail.com.
Scientific reports
|December 11, 2025
概括
研究人员使用生物异构体替代策略确定了新的循环素依赖性激酶9 (CDK9) 抑制剂. 这种方法产生了有前途的候选药物,具有强大的预测对CDK9的结合亲和力,这是癌症治疗的关键目标.
科学领域:
- 药用化学 医学化学
- 计算机化药物发现技术
- 分子生物学分子生物学
背景情况:
- 循环素依赖性激酶9 (CDK9) 对于转录延长和mRNA合成至关重要.
- 由于其在基因表达中的作用,CDK9是癌症治疗的有效治疗标.
研究的目的:
- 使用顺序生物异构体替代策略识别新型CDK9抑制剂.
- 提高潜在的CDK9抑制剂的化学多样性和预测生物活性.
主要方法:
- 通过生物异构架架替换生成大型复合库.
- 基于药的虚拟查和定量结构-活动关系 (QSAR) 建模.
- 密度功能理论 (DFT) 和分子动力学 (MD) 模拟用于稳定性和结合分析.
主要成果:
- 识别具有改善预测性质和结构新性的化合物 (例如50224760_85,9550,9724,31801).
- MD模拟证实了CDK9ATP结合口袋中的新联体的增强稳定性.
- 有约束力的自由能量分析表明与催化相关残留物有强烈的相互作用.
结论:
- 综合性策略成功地确定了一组多样化的强效CDK9抑制剂.
- 新型配体表现出预测的Ki值,与现有的实验性化合物相比.
- 这些发现支持已识别的化合物作为治疗CDK9相关疾病,特别是癌症的治疗剂的潜力.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K


